Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A… | ScholarDeck

Paper

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.

New research · Internal Medicine

British journal of haematology · 1mo

GuidelineBritish journal of haematology· Jun 2026

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.

Mamta Garg, Satarupa Choudhuri, Christopher Parrish … Ashutosh Wechalekar

Read paper

NephrologyGuidelineDiagnosisQ1IF 2.6

Early diagnosis of AL amyloidosis is linked to approximately 80% 5-year survival.

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.

Mamta Garg … Ashutosh Wechalekar

British journal of haematology · Jun 2026

Background

AL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect organ function.

Purpose

The aim of this guideline is to facilitate recognition and raise suspicion of amyloidosis.

Methods

With early-stage disease can expect approximately 80% survival at 5 years with contemporary treatment, compared to less than 30% for those with advanced disease.

Results

approximately 80%

how many people with early AL amyloidosis are expected to live for 5 years

More results

The survival of patients with systemic amyloid light-chain (AL) amyloidosis largely depends on the extent of end-organ damage.

“

Conclusion

The aim of this guideline is to facilitate recognition and raise suspicion of amyloidosis.

Read paper